Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07828522 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma

Name: F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma — clinical trial record (NCT07828522)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CAREMM-009

StatusNot Yet Recruiting

PhasePhase 2

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Started2026-10-01

View on ClinicalTrials.gov ↗

Institute of Hematology & Blood Diseases Hospital, China

318 trials monitored

See 9 trials at risk

Multiple Myeloma

1,228 trials monitored

See 75 trials at risk

This is a prospective, single-center, single-arm, exploratory pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of F182112 in combination with isatuximab and lenalidomide in transplant-eligible patients with newly diagnosed multiple myeloma. The study will also explore preliminary proof-of-concept signals of deep responses and minimal residual disease (MRD) negativity with this regimen, thereby informing the design of a subsequent phase II clinical trial.

Trial Details

NCT Number	NCT07828522
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Multiple Myeloma (MM), Transplant-eligible Patients
Enrollment	10 participants
Start Date	2026-10-01
Primary Completion	2027-10-09 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-18